Laboratory Values in Groups of Patients No. 1, 2, and 3
| Parameters . | Pretreatment Values . | P* . | Values at HbF Maximal Response . | P* . | ||||
|---|---|---|---|---|---|---|---|---|
| Group 1 (n = 12) . | Group 2 (n = 11) . | Group 3 (n = 5) . | Group 1 (n = 12) . | Group 2 (n = 11) . | Group 3 (n = 5) . | |||
| Hemoglobin g/dL | 8.4 ± 1.3 | 7.9 ± 1.0 | 8.9 ± 1.4 | NS | 9.7 ± 0.9† | 8.2 ± 0.7 | 8.7 ± 1.2 | .004 |
| MCV (fL) | 88.3 ± 12.3 | 82.9 ± 7.3 | 76.3 ± 9.7 | NS | 108.6 ± 7.7† | 100.7 ± 10.3† | 88.9 ± 15.5† | .03 |
| Neutrophils (×109/L) | 7.6 ± 2.4 | 7.0 ± 3.6 | 7.0 ± 2.9 | NS | 4.0 ± 2.5† | 3.6 ± 1.9† | 5.1 ± 2.4 | NS |
| Reticulocytes (×109/L) | 443 ± 213 | 450 ± 247 | 289 ± 132 | NS | 197 ± 89† | 284 ± 162† | 219 ± 68 | NS |
| HbF (%) | 6.3 ± 3.7 | 3.3 ± 2.1 | 1.4 ± 0.6 | .005 | 25.1 ± 5.0† | 14.4 ± 2.6† | 5.8 ± 2.6† | <.0001 |
| F reticulocytes (%) | 10.8 ± 6.8 | 5.3 ± 2.4 | 4.5 ± 1.0 | .01 | 34.6 ± 14.2† | 18.5 ± 5.3† | 10.6 ± 4.7 | .0005 |
| F cells (%) | 33.6 ± 14.5 | 20.1 ± 7.8 | 13.2 ± 6.1 | .01 | 76.2 ± 6.0† | 58.8 ± 10.4† | 30.3 ± 10.3 | <.0001 |
| F/F cell (pg) | 5.6 ± 1.6 | 3.8 ± 1.2 | 3.1 ± 0.9 | .005 | 11.1 ± 1.2† | 8.3 ± 1.2† | 5.4 ± 1.6 | <.0001 |
| P40 | 0.26 ± 0.06 | 0.30 ± 0.08 | 0.30 ± 0.07 | NS | 0.19 ± 0.02† | 0.19 ± 0.06 | 0.22 ± 0.03 | NS |
| P70 | 0.04 ± 0.04 | 0.07 ± 0.07 | 0.06 ± 0.06 | NS | 0.00 ± 0.01† | 0.02 ± 0.03 | 0.02 ± 0.03 | NS |
| Bilirubin (mg/L) | 47.5 ± 28.1 | 36.9 ± 24.6 | 30.2 ± 14.7 | NS | 26.0 ± 14.4† | 40.5 ± 28.8 | 35.7 ± 4.0 | NS |
| Parameters . | Pretreatment Values . | P* . | Values at HbF Maximal Response . | P* . | ||||
|---|---|---|---|---|---|---|---|---|
| Group 1 (n = 12) . | Group 2 (n = 11) . | Group 3 (n = 5) . | Group 1 (n = 12) . | Group 2 (n = 11) . | Group 3 (n = 5) . | |||
| Hemoglobin g/dL | 8.4 ± 1.3 | 7.9 ± 1.0 | 8.9 ± 1.4 | NS | 9.7 ± 0.9† | 8.2 ± 0.7 | 8.7 ± 1.2 | .004 |
| MCV (fL) | 88.3 ± 12.3 | 82.9 ± 7.3 | 76.3 ± 9.7 | NS | 108.6 ± 7.7† | 100.7 ± 10.3† | 88.9 ± 15.5† | .03 |
| Neutrophils (×109/L) | 7.6 ± 2.4 | 7.0 ± 3.6 | 7.0 ± 2.9 | NS | 4.0 ± 2.5† | 3.6 ± 1.9† | 5.1 ± 2.4 | NS |
| Reticulocytes (×109/L) | 443 ± 213 | 450 ± 247 | 289 ± 132 | NS | 197 ± 89† | 284 ± 162† | 219 ± 68 | NS |
| HbF (%) | 6.3 ± 3.7 | 3.3 ± 2.1 | 1.4 ± 0.6 | .005 | 25.1 ± 5.0† | 14.4 ± 2.6† | 5.8 ± 2.6† | <.0001 |
| F reticulocytes (%) | 10.8 ± 6.8 | 5.3 ± 2.4 | 4.5 ± 1.0 | .01 | 34.6 ± 14.2† | 18.5 ± 5.3† | 10.6 ± 4.7 | .0005 |
| F cells (%) | 33.6 ± 14.5 | 20.1 ± 7.8 | 13.2 ± 6.1 | .01 | 76.2 ± 6.0† | 58.8 ± 10.4† | 30.3 ± 10.3 | <.0001 |
| F/F cell (pg) | 5.6 ± 1.6 | 3.8 ± 1.2 | 3.1 ± 0.9 | .005 | 11.1 ± 1.2† | 8.3 ± 1.2† | 5.4 ± 1.6 | <.0001 |
| P40 | 0.26 ± 0.06 | 0.30 ± 0.08 | 0.30 ± 0.07 | NS | 0.19 ± 0.02† | 0.19 ± 0.06 | 0.22 ± 0.03 | NS |
| P70 | 0.04 ± 0.04 | 0.07 ± 0.07 | 0.06 ± 0.06 | NS | 0.00 ± 0.01† | 0.02 ± 0.03 | 0.02 ± 0.03 | NS |
| Bilirubin (mg/L) | 47.5 ± 28.1 | 36.9 ± 24.6 | 30.2 ± 14.7 | NS | 26.0 ± 14.4† | 40.5 ± 28.8 | 35.7 ± 4.0 | NS |
Abbreviations: NS, not significant, P > .05; P40 and P70, polymer tendency at 40% and 70% oxygen saturation in the F-cell population.
P values from Kruskal-Wallis test comparing the values of the three groups either before treatment or at the time of HbF maximal response.
P < .05 from Wilcoxon signed test within group categories, comparing the pretreatment values with values at HbF maximal response.